Emergent BioSolutions (NYSE:EBS) Stock Price Down 7% - What's Next?

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report)'s share price dropped 7% on Monday . The company traded as low as $10.12 and last traded at $10.46. Approximately 376,780 shares were traded during trading, a decline of 61% from the average daily volume of 954,547 shares. The stock had previously closed at $11.25.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on EBS shares. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. StockNews.com lowered shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Friday, January 24th. Finally, Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Thursday, November 7th.

Emergent BioSolutions Stock Performance

The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The company has a fifty day moving average price of $9.65 and a 200 day moving average price of $9.31. The stock has a market cap of $568.24 million, a P/E ratio of -2.56 and a beta of 1.62.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 EPS for the quarter, topping the consensus estimate of $0.49 by $0.88. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The company had revenue of $293.80 million during the quarter, compared to the consensus estimate of $328.72 million. During the same period in the previous year, the firm posted ($1.44) earnings per share. On average, equities analysts expect that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Institutional Trading of Emergent BioSolutions

Several institutional investors and hedge funds have recently modified their holdings of the stock. SBI Securities Co. Ltd. bought a new stake in shares of Emergent BioSolutions in the 4th quarter worth $63,000. Stifel Financial Corp purchased a new position in Emergent BioSolutions during the third quarter worth about $96,000. FORA Capital LLC bought a new stake in Emergent BioSolutions in the 3rd quarter worth about $103,000. Landscape Capital Management L.L.C. purchased a new stake in Emergent BioSolutions in the 3rd quarter valued at about $141,000. Finally, Entropy Technologies LP bought a new position in shares of Emergent BioSolutions during the 3rd quarter worth approximately $155,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.